Oct 7, 2026 08:30AM
Oct 7, 2026 08:30AM
Sep 22, 2026 08:31AM
Sep 22, 2026 08:30AM
Sep 16, 2026 08:30AM
Aug 27, 2026 08:30AM
Aug 27, 2026 08:30AM Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
Aug 27, 2026 08:30AM
Aug 12, 2026 08:32AM
Aug 12, 2026 08:30AM
Aug 6, 2026 08:31AM
Aug 6, 2026 08:31AM
Aug 6, 2026 08:30AM
Aug 6, 2026 08:30AM Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Model
Jul 7, 2026 08:33AM
Jul 7, 2026 08:30AM
Jun 11, 2026 08:30AM
Jun 11, 2026 08:30AM
Mar 3, 2026 08:46AM
Mar 3, 2026 08:45AM
Mar 3, 2026 08:45AM Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
Feb 5, 2026 08:45AM
Feb 5, 2026 08:45AM
Jan 15, 2026 08:45AM
Jan 15, 2026 08:45AM
Aug 21, 2024 09:00AM
Aug 14, 2024 09:00AM
Jul 17, 2024 09:00AM Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
Jun 25, 2024 09:00AM
Apr 16, 2024 09:00AM
Feb 22, 2024 08:00AM
Dec 13, 2023 09:00AM
Nov 7, 2023 09:00AM
Aug 15, 2023 08:30AM
Jul 13, 2023 08:30AM Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
Jul 5, 2023 09:00AM
Jun 22, 2023 09:00AM
Mar 28, 2023 09:03AM
Mar 28, 2023 09:00AM
Mar 16, 2023 09:00AM
Dec 15, 2022 09:00AM
Nov 30, 2022 09:00AM Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer
Nov 15, 2022 09:00AM
Oct 26, 2022 09:00AM
Sep 29, 2022 09:00AM
Sep 13, 2022 09:00AM
Sep 8, 2022 09:15AM
Aug 16, 2022 09:00AM
Aug 3, 2022 09:00AM Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada
Jul 28, 2022 09:00AM

335,122 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All